Quest Diagnostics (DGX) PT Raised to $190 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall St rises as oil falls heading into US midterm elections
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts DGX Hot Sheet
Price: $249.97 -0.73%
Rating Summary:
15 Buy, 17 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 24 | New: 16
Rating Summary:
15 Buy, 17 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 24 | New: 16
Join SI Premium – FREE
Barclays analyst Stephanie Davis raised the price target on Quest Diagnostics (NYSE: DGX) to $190.00 (from $185.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Bright Minds Biosciences Inc. (DRUG) PT Lowered to $107 at Baird amid partial clinical hold
- Merck (MRK) PT Raised to $140 at Freedom Broker
- Tempus AI Inc (TEM) PT Raised to $89 at Needham
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
